Company news
HeiLongJiang ZBD Pharmaceutical Co., Ltd. news
Latest news releases, newest first. Pick a year for every news release, call and deck from that year.
(603567)"Heilongjiang ZBD Pharmaceutical Co., Ltd."Announcement on Progress in Providing Guarantee for Wholly-owned Subsidiary
October 28, 2026
(603567)"Heilongjiang ZBD Pharmaceutical Co., Ltd."Announcement on Departure of the Director and Board Secretary and Designation of the Chairman to Act as the Board Secretary
October 28, 2026
(603567)"Heilongjiang ZBD Pharmaceutical Co., Ltd."Notice on Convening the 5th Extraordinary General Meeting in 2026
October 27, 2026
(603567)"Heilongjiang ZBD Pharmaceutical Co., Ltd."Announcement on Termination of Certain Raised Funds Investment Projects and Continued Deposit of Remaining Raised Funds in Special Accounts for Raised Funds
October 27, 2026
(603567)"Heilongjiang ZBD Pharmaceutical Co., Ltd."Announcement on Resolutions of the 6th Meeting of the 6th Board of Directors
October 27, 2026
Announcement on Progress in Providing Guarantee for Wholly-owned Subsidiary
September 3, 2026
Announcement on Convening the 2026 Semi-annual Performance Briefing
September 2, 2026
Announcement on Pledge of Certain Shares Held by the Controlling Shareholder
August 31, 2026
Semi-annual Report for 2026
August 28, 2026
Announcement on Change of Sponsor Representative for Continuous Supervision
August 25, 2026
Announcement on Resolutions of the 4th Extraordinary General Meeting in 2026
August 18, 2026
Announcement on Progress of Provision of Guarantee for an Investee Company
August 13, 2026
Announcement on Provision of Guarantee Limit for Wholly-owned Subsidiary
July 30, 2026
Announcement on Abnormal Fluctuations in Stock Trading
July 17, 2026
Notice on Convening the 3rd Extraordinary General Meeting in 2026
July 14, 2026
Announcement on Implementation of Repurchase and Cancellation of Partial Restricted Stocks under 2023 Restricted Stock Incentive Plan
July 13, 2026
Announcement on Partial Reply to the Shanghai Stock Exchange's Information Disclosure Supervisory Inquiry Letter on the Company's 2025 Annual Report
July 8, 2026
Indicative Announcement on the Proposed Extension of the Pledge of Certain Shares Held by the Controlling Shareholder
July 6, 2026
Indicative Announcement on Proposed Extension of Pledge of Partial Shares by the Controlling Shareholder
June 29, 2026
Announcement on Extension of Pledge of Partial Shares by the Controlling Shareholder
June 25, 2026
Announcement on Providing Guarantee for Wholly-owned Subsidiary
June 24, 2026
Announcement on Abnormal Fluctuations in Stock Trading
June 18, 2026
Announcement on Resolutions of the 2nd Extraordinary General Meeting in 2026
June 10, 2026
Notice on Convening the 2nd Extraordinary General Meeting in 2026
May 25, 2026
Announcement on Inability to Timely Repay the Raised Funds Temporarily Used to Supplement Working Capital
May 13, 2026
Announcement on Progress in Providing Guarantee for Wholly-owned Subsidiaries
May 7, 2026
Announcement on Proposed Inclusion of Some Drugs in the Centralized Volume Procurement of National Chinese Patent Medicine Procurement Alliance
May 6, 2026
Announcement on Completion of the Pledge Release on the Remaining Pledged Shares of the Non-publicly Issued Exchangeable Corporate Bonds by the Controlling Shareholder
April 30, 2026
Special Report on Deposit, Management and Actual Use of Raised Funds in 2025
April 29, 2026
Announcement on Postponement of Disclosure of 2025 Annual Report
April 28, 2026
Announcement on Implementing Cancellation of Repurchased Shares and Share Changes
April 27, 2026
Indicative Announcement on Premature Delisting of the Non-public Offering of Exchangeable Corporate Bonds by the Controlling Shareholder (Phase II) and the Proposed Release of the Remaining Pledged Shares
April 21, 2026
Announcement on Resolutions of the 1st Extraordinary General Meeting in 2026
April 20, 2026
Indicative Announcement on Change in Equity of Controlling Shareholder
April 16, 2026
Indicative Announcement on Completion of the Delisting of the Non-public Offering of Exchangeable Corporate Bonds by the Controlling Shareholder (Phase I) and the Proposed Release of the Remaining Pledged Shares
April 13, 2026
Indicative Announcement on Change in Equity of Controlling Shareholder Reaching 1% Scale
April 9, 2026
Announcement on Completion of Supplemental Share Pledge Procedures for the Non-publicly Issued Exchangeable Corporate Bonds by the Controlling Shareholder
April 2, 2026
Indicative Announcement on Adjusting Conversion Price of Non-publicly Issued Exchangeable Corporate Bonds Held by Controlling Shareholders
April 1, 2026
Notice on Convening the 1st Extraordinary General Meeting in 2026
March 30, 2026
Indicative Announcement on Controlling Shareholder’s Proposed Supplementary Pledge of Shares for the Non-public Issuance of Exchangeable Corporate Bonds
March 26, 2026
Announcement on Resignation of Chairman of the Board of Directors, Election of a New Chairman and Adjustment of Members of Special Committees of Board of Directors
March 13, 2026
Announcement on Obtaining Notice of Approval for Marketing Application of Chemical APIs of Branch
March 10, 2026
Announcement on Earnings Preannouncement for 2025
January 30, 2026
Announcement on Pledge and Release of Pledge of Partial Shares of Controlling Shareholders
December 19, 2025
Announcement on Resolutions of the 3rd Extraordinary General Meeting in 2025
December 11, 2025
Announcement on Result of Shareholding Reduction by Shareholder with Over 5% Shares
December 10, 2025
Announcement on Providing Additional Guarantee Amount for Wholly-owned Subsidiary
December 5, 2025
Announcement on Obtaining Drug Registration Certificate by the Wholly-owned Subsidiary
December 2, 2025
Announcement on Renewing Engagement of Accounting Firm
November 25, 2025
Report for Q3 2025
October 27, 2025